Possible Bearish Signals With Vera Therapeutics Insiders Disposing Stock

In the last year, many Vera Therapeutics, Inc. (NASDAQ:VERA) insiders sold a substantial stake in the company which may have sparked shareholders' attention. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.

Check out our latest analysis for Vera Therapeutics

Advertisement

Vera Therapeutics Insider Transactions Over The Last Year

In the last twelve months, the biggest single sale by an insider was when the Chief Financial Officer, Sean Grant, sold US$735k worth of shares at a price of US$40.06 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$33.37). So it is hard to draw any strong conclusion from it.

In the last year Vera Therapeutics insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
NasdaqGM:VERA Insider Trading Volume January 20th 2025

I will like Vera Therapeutics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Insiders own 0.8% of Vera Therapeutics shares, worth about US$17m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About Vera Therapeutics Insiders?

The fact that there have been no Vera Therapeutics insider transactions recently certainly doesn't bother us. Our analysis of Vera Therapeutics insider transactions leaves us cautious. But we do like the fact that insiders own a fair chunk of the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Vera Therapeutics. For instance, we've identified 3 warning signs for Vera Therapeutics (2 are a bit concerning) you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGM:VERA

Vera Therapeutics

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.

High growth potential with excellent balance sheet.

Advertisement

Weekly Picks

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.3% undervalued
54 users have followed this narrative
3 users have commented on this narrative
24 users have liked this narrative
TO
Tokyo
MC logo
Tokyo on LVMH Moët Hennessy - Louis Vuitton Société Européenne ·

EU#4 - Turning Heritage into the World’s Strongest Luxury Empire

Fair Value:€750.0428.6% undervalued
5 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
GOOGL logo
WealthAP on Alphabet ·

The "Easy Money" Is Gone: Why Alphabet Is Now a "Show Me" Story

Fair Value:US$386.4316.1% undervalued
66 users have followed this narrative
1 users have commented on this narrative
20 users have liked this narrative

Updated Narratives

PI
PittTheYounger
DAL logo
PittTheYounger on Delta Air Lines ·

Delta loses shine after warning of falling travel demand, but still industry leader

Fair Value:US$63.2118.7% overvalued
18 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RA
Ravedigga
ALRT logo
Ravedigga on Defence Holdings ·

Project Ixian Accelerated Rollout will Drive Valuation Expansion to ÂŁ0.0150.

Fair Value:UKÂŁ0.01510.7% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TO
Tokyo
SIE logo
Tokyo on Siemens ·

EU#5 - From Industrial Giant to the Digital Operating System of the Real World

Fair Value:€319.519.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OO
NEO logo
OOO97 on Neo Performance Materials ·

Undervalued Key Player in Magnets/Rare Earth

Fair Value:CA$25.3317.8% undervalued
76 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.3% undervalued
54 users have followed this narrative
3 users have commented on this narrative
24 users have liked this narrative
BL
BlackJesus
ADBE logo
BlackJesus on Adobe ·

The Strategic Revaluation of Adobe: A Critical Analysis of Market Sentiment

Fair Value:US$46042.0% undervalued
34 users have followed this narrative
2 users have commented on this narrative
22 users have liked this narrative
Advertisement